Small Cap Feast
Small Cap Feast – 03 December 2018
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 920
Total number of AIM Companies trading: 850*
* As at 26 November 2018
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 26 November 2018
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): *
Total number of Standard List Companies trading: *
* As at 26 November 2018
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
SEEIT will be the first UK-listed investment fund of its kind to invest exclusively in the energy efficiency sector. Looking to raise £150m. Due 11 Dec
AJ Bell—one of the largest investment platforms in the UK—Expects to publish prospectus end Nov. FYSep18—revenues up 19% to £89.7 million, profit before tax up 31% to £28.4 million. Secondary sell down, Due December.
Sirius Aircraft Leasing Fund targeting a raise of US$250m – objective is to provide investors with an attractive level of regular income and capital returns through investing primarily in used, single-aisle aircraft. Due 5 Dec
MOD Resources—(ASX:MOD) A$78.7m mkt cap. Copper exploration and development company focused on the central and western Kalahari Copper Belt in Botswana. Introduction only. Due c.26 Nov.
Main Market (Specialist Funds)
The Global Sustainability Trust -aiming for attractive risk-adjusted returns by investing primarily in private market investments that are expected to have a positive environmental and social impact raising c.£200m. Due end Nov.
Crossword Cybersecurity PLC* (NEX:CCS)—the technology commercialisation company focusing exclusively on the cyber security sector is investigating the possibility of AIM admission. The Company is proposing to raise up to £2.25 million before the end of December, conditional on Admission.
Manolete Partners—leading UK insolvency litigation financing business looking to join AIM raising £16.3m as a placing and £13.1 realised by the selling shareholder at 175p. Market cap £76.3m, expected 14 December
Titon holdings—international manufacturer and supplier of ventilation systems and window and door hardware. No capital raise. Due 10 Dec. Mkt cap c.£22m.
Greenfields Petroleum (TSX-V:GNF) production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected early December.
Finncap—proposed acquisition of M&A adviser Cavendish Corporate Finance and AIM admission. Offer raising £3.75m of new money and £1.25m for selling shareholders, market cap of £47.1m. Due 5 December
The Panoply parent company of a digitally native technology services group founded in 2016 with the aim of identifying and acquiring best-of-breed specialist information technology and innovation consulting businesses across Europe, is looking to join AIM. Offer £5m new capital, £400k sell-down, market cap of £30m, expected late 4 Dec 2018.
McColl’S Retail (MCLS.L) 113p £138m
Q4 and FYDec18 trading update. Total revenue down (0.5)% in Q4; up 8.3% for the full-year reflecting the annualisation of the 2017 acquisition.
Total like-for-like (LFL)1 sales flat at 0% in Q4, an improvement on Q3 supported by a strong performance in tobacco; with full-year LFL sales down (1.4)%. 59 convenience store refreshes completed in the year, delivering average sales uplifts above 5%. 11 new convenience stores acquired in 2018. Continuation of estate optimisation programme with 66 under-performing newsagents and smaller convenience stores removed in the year. Further sale and leaseback transactions completed in Q4 generating full-year cash proceeds of £25m and significant profits on disposal
Year-end net debt materially lower than expected at around £100m. In light of transitional challenges and continued difficult trading conditions, adjusted EBITDA for FY18 now expected to be around £35m.
RhythmOne (RTHM.L) 180p £141.55m
The “global advertising technology company, announced that it has partnered with Placed – one of the leaders in location-driven insights and ad intelligence – to offer its clients access to a new measurement solution that quantifies the impact of digital and linear TV campaigns in driving consumers to retail stores. RhythmOne’s solution integrates Placed’s TV measurement solution, Placed Attribution for TV, which leverages in-store attribution data to match linear TV ad exposure with desktop, mobile, and connected TV (CTV) ad exposures.”
“By integrating the Placed Attribution for TV with our platform, we have the advantage of offering clients consolidated, easy-to-interpret reports that clearly prove whether their marketing efforts have moved the needle.”
Urban Exposure (UEX.L) 84p £133m
Lending update from the specialist residential development finance firm and asset manager.
In the period from 31 Oct 2018 to 30 Nov 2018, the Company has successfully closed new loans totalling £110m, bringing total lending commitments since the IPO to c. £340m. The loans cover development projects across the country, including Chelmsford, Brentwood, Horley and Luton. Since the IPO, the Company has committed to the financing of projects representing the construction of 1,531 residential units, of which 208 are affordable housing units, and 45,000 sq ft of commercial real estate (including office space, retail and a hotel). The return profile of the new loans remains in line with expectations at IPO.
The Company is working on a number of other new loans which it expects to close by year-end.
W Resources (WRES.L) 0.52p £28.49m
“The tungsten, copper and gold mining company with assets in Spain and Portugal, is delighted to announce the first shipment of tungsten concentrate from its La Parrilla Mine following the early start-up of production as part of a planned staged build-up to full mine production in H1 2019.
“We are delighted to have delivered our first shipment of tungsten concentrate to our European customer on 30 November 2018. W has now commenced the first of a three stage production programme which allows the Company to generate revenue and cash flow ahead the move to large scale production in 2019 at a planned run rate of 2,500 tonnes per annum of tungsten concentrate. Export shipment size will build through December and the new year.” “
Mercia Technologies (MERC.L) 29p £89.5m
HYSep18 results from the national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high growth potential from the UK regions.
£9.2m net invested in 11 portfolio companies during the period (H1 2017: £9.7m invested in nine portfolio companies). Significant commercial milestones achieved by direct investment portfolio companies include: Oxford Genetics – won its largest multi-million pound contract to date with a global ecommerce provider of reagents and tools to the research and clinical community
nDreams – won its largest multi-million pound contract to date with a high-profile global technology company.
Funds under management at the period end were £394.9m (H1 2017: £336.5m).
33.3% increase in earnings per Ordinary share to 0.64p (H1 2017: 0.48p). NAV per share was 41.3p (H1 2017: 41.1p).
Phoenix Global Mining (PGM.L) 30p £9.5m
The North American-focused base and precious metals exploration and development company, announced further results from the Company’s ongoing drilling programme at the Empire Copper Project in Idaho, USA.
RedStar zone,: Located 330m north-northwest of the Empire open pit resource shows a transition to a high-grade silver and lead system. Three drill holes in Oct returned assays of 1,111 grams per tonne (“g/t”) (35.7 oz) silver and 20% lead over a 1.5 m intersection at RedStar.
Drilling in and around the Empire Mine oxidation resource envelope, which covers a 1 km strike length and is the subject of the ongoing feasibility study, returned high grade copper and silver assay results and continued to confirm the presence of the underlying sulphide mineralisation. These results “help confirm that the Empire mineralised system extends well beyond the near surface copper-oxide resource which is currently the subject of our Empire Mine Feasibility Study.”
Faron Pharma (FARN.L) 58.5p £18.15m
The clinical stage biopharmaceutical company, today announces that its Clinical Trial Application (CTA) to conduct a Phase I/II study with Clevegen, its wholly-owned novel precision cancer immunotherapy drug, in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA). Patient recruitment into the Phase I/II MATINS study is expected to commence shortly at Helsinki and Oulu University Hospitals in Finland.
The same CTA is also under review by the UK’s regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA) for opening sites in the UK (the Royal Marsden Hospital in London and the Queen Elisabeth Hospital in Birmingham). Clevegen is a novel anti-Clever-1 antibody, which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.
ULS Technology (ULS.L) 77.36p £50.08m
The provider of online B2B platforms for the UK conveyancing and financial intermediary markets, announces its half yearly results for the six months to 30 Sept 2018. The Group continued to increase its market share and grow revenue and profits during the period despite housing market transactions being lower year-on-year.
Revenue increased by 3% to £15.79m (H1 2017: £15.28m). Underlying PBT increased by 6% to £2.89m (H1 2017: £2.74m)
Adjusted basic EPS increased by 7% to 3.73p (H1 2017: 3.49p)
“The macro-economic environment for the last few months has been uncertain. This has fed through to a reduction in housing activity. The feeling in the market is that some potential house buyers are sitting on their hands until there is greater clarity over economic prospects and house prices before entering the market.” “The medium-term prospects for technology providers to the housing market remain positive and therefore we will continue to invest in both sales and product to deliver long-term profitable growth.”
BATM (BVC.L) 49.4p £196.5m
The provider of real-time technologies for networking solutions and medical laboratory systems, announces that Telco Systems, a wholly-owned high-end software development and design business within the Group’s Networking & Cyber division, has advanced its strategic partnership with Arm, the industry’s leading supplier of semiconductor IP, in becoming a part of the recently-launched Arm® Neoverse™ ecosystem.
Arm Neoverse is the new brand and roadmap of technologies to enable a new and transformative cloud infrastructure designed to support the demands of a trillion intelligent devices. Telco Systems is a platform provider within the Arm Neoverse ecosystem based on its NFVTime virtualisation technology. “We congratulate Arm on the launch of Arm Neoverse and we look forward to working with them to develop a full ecosystem of virtual network function services to enable the networks of the future.”
Block Commodities (NEX:BLCC) 0.03p £1.5m
The innovative commodity trader operating in Africa, is pleased to announce the progress in the pilot project being carried out in Uganda in partnership with Pure Grow Africa. The Company’s Head of African Operations, Clinton van Eden, has recently visited farmers in remote areas in Uganda, along with Bobby Juuko Kimbugwe, CEO at Pure Grow Africa.
The Farmer 3.0 pilot project was launched in Sept 2018 and will aim to supply up to 1,000 Ugandan smallholder farmers with utility token-based loans for farmers selected by Pure Grow Africa to purchase fertiliser and gain access to appropriate technology to enhance production.
The results of the meetings with farmers highlighted the need for alternative funding for fertilisers and pesticides, access to technical training and markets beyond the local level. Remains Suspended pending a potential takeover.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.